News & Press Releases




13 June 2024
Regulatory

Integrum has carried out a directed new issue of 961,539 series B shares, raising proceeds of approximately SEK 50 million

Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) has successfully carried out an issue of 961,539 new series B shares, at a subscription price of SEK 52 per share, raising proceeds of approximately SEK 50 million (the “Directed Issue”).

read more
13 June 2024
Regulatory

Integrum intends to carry out a directed new issue of series B shares of approximately SEK 50 million

Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) announces its intention to carry out an issue of series B shares of approximately SEK 50 million directed to Swedish and international institutional investors (the “Directed Issue”). Integrum has appointed Carnegie Investment Bank AB (publ) (“Carnegie”) as Sole Global Coordinator and Bookrunner to explore the conditions to carry out the Directed Issue through an accelerated book-building procedure.

read more
13 June 2024

Integrum signs Memorandum of Understanding with Coapt for the use of its pattern recognition technology with the e-OPRA[TM] Implant System

Mölndal, Sweden – June 13, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a Memorandum of Understanding with the American medtech company Coapt LLC, with the intention to provide Integrum the possibility to combine Coapt’s pattern recognition technology with the continued development of e-OPRA[TM] Implant System.

read more
10 June 2024
Regulatory

Integrum enters collaboration and distribution agreement with Hanger – the leading provider of amputee care and prosthetics in the US

Mölndal, Sweden – June 10, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has entered a commercial collaboration and distribution agreement with Hanger, the leading provider of amputee care and prosthetics in the US that delivers care to almost one-third of all amputees in the country. Within the framework of the agreement, Integrum’s prosthetic product portfolio will be made available to eligible patients at any of Hanger Clinic’s 900 patient care facilities nationwide as well as distributed to other facilities. The agreement will take effect on June 10, 2024.

read more
30 May 2024
Regulatory

A Record Year in Sales

FOURTH QUARTER 2023/24 (FEBRUARY – APRIL) · Net sales amount to 26.1 (18.1) MSEK, which is an increase of 43.7% compared with the corresponding period last year. The growth in the US market and in Rest of the World is 15.1% and 147 % compared with the corresponding period last year, respectively. · Operating result amounts to 2.6 (-7.2) MSEK (EBIT 10.1%). The operating result amounted to -1.8 MSEK (EBIT -7.0%) excluding currency effects of 4.5 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to 2.3 (-6.1) MSEK, which resulted in earnings per share of SEK 0.1 (-0.33). · Cash flow from operating activities amounts to 2.8 MSEK (-6.4), change in working capital was -10.2 MSEK (3.8) and investing activities -3.7 (-1.7). Total cash flow was -11.5 (-4.4) MSEK. Liquid assets as of 2024-04-30 amount to 16.9 (41.9) MSEK, not including 33.6 MSEK in accounts receivables.   Significant events in the quarter · Independent researchers published an article showing that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times while simultaneously improving quality of life. · Integrum also announced that the company has entered distribution agreements in Israel and in the UK. Significant events after the quarter · The company has extended its credit facility and is finalizing a factoring setup, which together will make another 30 MSEK available to support expansion.    1 MAY 2023 – 30 APRIL 2024 (12 MONTHS) · Net sales amounted to 104.1 (74.3) MSEK, an increase of 40.2% compared with the corresponding period in the previous year. The growth in the US market and in Rest of the World is 25% and 95% compared with the corresponding period last year, respectively. · Operating result amounted to 6.5 (-19.7) MSEK. The operating result amounted to 0.7 MSEK (EBIT 0.7%) excluding currency effects of 5.8 MSEK, most of which are unrealized internal accounts receivables. · Profit after tax amounted to 4.2 (-16.2) MSEK, which resulted in earnings per share of SEK 0.2 (-0.9). · Cash flow from operating activities amounts to 8.0 (-20.6) MSEK. Total cash flow was -25.0 (-33.4) MSEK. Significant events in the year · Integrum appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan. Jeff has more than 20 years of success in the surgical and medical device   industry and has a proven track record of successfully developing and leading highly effective sales teams. · In Q2, The Centers for Medicare and Medicaid Services (CMS) granted the external prosthetic connection device Axor II™ a new reimbursement code. The new code is connected to a set reimbursement that will help to drive growth in the US. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss. · Also during the year, the company entered into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.

read more
29 May 2024
Regulatory

Integrum receives market approval for OPRA[® in Israel]

Mölndal, Sweden – May 29, 2024 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has received market approval for the OPRA[®] Implant System in Israel.

read more
24 May 2024

Integrum AB: Invitation to the Fourth Quarter 2023/24 Results Presentation

Mölndal, Sweden – May 24, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its fourth quarter 2023/24 results on May 30, 2024 at 14:00 CEST.

read more
15 May 2024

Integrum has been granted a registered trademark for OPRA® Implant System in the EU

Mölndal, Sweden – May 15, 2024 — Integrum (publ) (Nasdaq First North Growth Marketing: INTEG B) announces that the European Union Intellectual Property Office, EUIPO, has approved Integrum’s product registration application for the OPRA® Implant System.

read more
3 May 2024

Integrum launches short video documentary to showcase the company’s efforts to treat combat amputees in Ukraine

Mölndal, Sweden – May 3, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has launched a short video documentary about the company’s Center of Excellence in Kyiv, Ukraine. During Dr Rickard Brånemark’s latest training session at the end of April, the center was visited by several delegations with politicians, company leaders and military representatives, and the video documentary was screened to introduce discussions on the future of trauma healthcare in Ukraine. Among the visitors were the Swedish Minister for Social Services, Camilla Waltersson Grönvall.

read more
2 May 2024

Integrum expands its product offering to the United Kingdom market

Mölndal, Sweden – May 2, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with LEDA Orthopaedics Ltd., a local medical device distributor specialized in niche trauma implants, hand surgery prostheses and unique solutions for orthopaedic procedures, to introduce OPRA[TM] Implant System in the United Kingdom.

read more
26 March 2024

Integrum expands its product offering into the Israeli market

Mölndal, Sweden – March 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with AMI Technologies, a leading local medical device distributor, to introduce the OPRA[TM] Implant System in Israel.

read more
19 March 2024

Health economic study shows positive outcome using Integrum’s OPRA[TM] Implant System over socket prostheses in transfemoral amputees

Mölndal, Sweden – March 19, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that a team of independent researchers, from six prestigious academic and clinical institutions in the US, have published a health economic article analyzing potential effects on societal cost-control and quality-of-life when utilizing osseointegrated transfemoral prostheses compared to traditional socket prostheses. The study’s meta-analyses show that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times while simultaneously improving quality of life. The article will be featured in the March 2024 issue of Bone & Joint Open.

read more
29 February 2024
Regulatory

A new record revenue quarter with 61% growth

THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of SEK 0.05 (-0.74). · Cash flow from operating activities amounts to 2.0 MSEK (-14.1), change in working capital was -2.9 MSEK (8.2) and investing activities -4.0 (-1.2). Total cash flow for the period was -5.0 (-7.1) MSEK. Liquid assets as of 2024-01-31 amount to 28.4 (46.3) MSEK, not including 29.2 MSEK in accounts receivables. Significant events in the third quarter · The US Department of Defense decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. The study will be performed by the Walter Reed National Military Medical Center. Integrum will supply OPRA™ Implant Systems on commercial terms. · The company held a pre-submission meeting with the US Food and Drug Administration (FDA). Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application for Integrum’s OPRA™ Implant System in transhumeral amputations based on existing clinical data. · Integrum received its final MDR certification. The company’s OPRATM Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.

read more
29 February 2024
Regulatory

CORRECTION A new record revenue quarter with 61% growth

The figures for Rights of Use assets (6,620 KSEK) were missing in the previous report and have now been added. The total sums for Fixed Assets and the Balance Sheet remain the same. THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of SEK 0.05 (-0.74). · Cash flow from operating activities amounts to 2.0 MSEK (-14.1), change in working capital was -2.9 MSEK (8.2) and investing activities -4.0 (-1.2). Total cash flow for the period was -5.0 (-7.1) MSEK. Liquid assets as of 2024-01-31 amount to 28.4 (46.3) MSEK, not including 29.2 MSEK in accounts receivables. Significant events in the third quarter · The US Department of Defense decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. The study will be performed by the Walter Reed National Military Medical Center. Integrum will supply OPRA™ Implant Systems on commercial terms. · The company held a pre-submission meeting with the US Food and Drug Administration (FDA). Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application for Integrum’s OPRA™ Implant System in transhumeral amputations based on existing clinical data. · Integrum received its final MDR certification. The company’s OPRATM Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.

read more
23 February 2024

Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation

Mölndal, Sweden – February 23, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024 at 14:00 CEST.

read more
31 January 2024
Regulatory

Integrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine

Mölndal, Sweden – January 31, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.

read more
20 December 2023

Integrum establishes Center of Excellence in Ukraine

Mölndal, Sweden – December 20, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.

read more
15 December 2023

Integrum’s MDR certification is completed for the OPRA[TM] Implant System

Mölndal, Sweden – December 15, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has received its final MDR certification, thus finalizing the review process of the company’s products under the new EU medical device regulatory (MDR) framework. The company’s OPRA[TM] Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss.

read more
4 December 2023
Regulatory

Record sales and profitability

SECOND QUARTER 2023/24 (MAY – JULY) · Net sales amounted to SEK 27.6 (20.2) million, which is an increase of 36% compared with the corresponding period last year. The growth in the US market is 27% compared with the corresponding period last year. · Operating profit amounted to SEK 6.5 (0.9) million. Excluding direct currency effects, the operating profit is at 3.8 MSEK (-5.2). · Profit/loss after tax amounted to SEK 3.9 (2.3) million, which resulted in earnings per share of SEK 0.21 (0.13). · Cash flow from operating activities amounted · to SEK 6.8 (-5.3) million. Liquid assets as of 2023-10-31 amounted to SEK 33.3 (53.4) million. Significant events in the quarter · In the quarter, The Centers for Medicare and Medicaid Services (CMS) granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code is connected to a set reimbursement that will help to drive growth in the US. · The company appointed Alex Winber as Vice President Sales and Marketing with full focus on the US. The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.  · The Board of Directors initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™ Implant System. · The company received a Unitary Patent approval pertaining to NeuromotusTM. The patent grants immediate proprietary rights to Integrum in 17 separate European countries. · During the quarter, the company entered into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon. · In the period, Scott Flora was elected as full member of the company’s board at the annual general meeting. · CEO Rickard Brånemark moderated a workshop in Ukraine on 21 September, focusing on war-related amputee care.  Also he visited Kyiv, Ukraine, to treat wounded soldiers, to train Ukrainian orthopaedic surgeons in advanced amputee care and to support the build-up of expanded trauma healthcare. 1 MAY – 31 OCTOBER 2023/24 (6 MONTHS) · Net sales amounted to SEK 48.0 (37.5) million, which is an increase of 28% compared with the corresponding period last year. The growth in the US market is 22% compared with the corresponding period last year · Operating profit amounted to SEK 3.5 (1.2) million. · Profit/loss after tax amounted to SEK 1,2 (1.8) million, which resulted in earnings per share of SEK 0,06 (0.1). · Cash flow from operating activities amounted to SEK 4.2 (-11.5) million.  · Integrum announced that Shirley Ryan AbilityLab has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.

read more
30 November 2023
Regulatory

Integrum AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

Mölndal, Sweden – November 30, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).

read more
28 November 2023

Integrum AB: Invitation to the Second Quarter 2023/24 Results Presentation

Mölndal, Sweden – November 28, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2023/24 results on December 4, 2023 at 14:00 CEST.

read more
13 November 2023

Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data

Mölndal, Sweden – November 13, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has held a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the use of Integrum’s OPRA™ Implant System in transhumeral amputations. Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application based on existing clinical data.

read more
10 November 2023

Clinical study of Integrum’s OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense

Mölndal, Sweden – November 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the US Department of Defense has decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced,  the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA™ Implant Systems to Walter Reed on commercial terms.

read more
10 November 2023
Regulatory

Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023

Mölndal, Sweden – November 10, 2023 — For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added. All other items remain the same. Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.

read more
9 November 2023
Regulatory

Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023

Mölndal, Sweden – November 9, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.

read more
30 October 2023

Integrum’s OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations

Mölndal, Sweden – October 30, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company’s OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US

read more
27 October 2023

Integrum moves into Turkey

Mölndal, Sweden – October 27, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.

read more
12 October 2023

Integrum announces the world’s first long-term integrated bionic hand enriched with motor and sensory AI

Mölndal, Sweden, October 12, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company’s innovative implantable solution, has shown successful results. The groundbreaking system represents a future standard of advanced prosthetic solutions.

read more
10 October 2023

Integrum receives a Unitary Patent for Neuromotus in the EU

Mölndal, Sweden, October 10, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has received a Unitary Patent approval pertaining to Neuromotus[TM] – a clinical innovation aimed at treating patients suffering from Phantom Limb Pain. The new patent process, which was installed by the EU in June 2023, grants immediate proprietary rights to Integrum in 17 separate European countries.

read more
10 October 2023

Integrum welcomes Scott Flora as full board member

Mölndal, Sweden – October 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora was recently elected as full member of the company’s board at the annual general meeting.

read more
27 September 2023

Integrum attends international expert workshop on osseointegration and bionic limb reconstruction

Mölndal, Sweden, September 27, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is attending an international meeting and workshop event gathering experts in the field of osseointegration and bionic limb reconstruction, at the prestigious Rizzoli Orthopaedic Institute at the University of Bologna, Italy, on October 18–19[th].

read more
19 September 2023

Integrum participates in war-related amputee care workshop to support amputee care in Ukraine

Mölndal, Sweden, September 19, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company’s CEO Rickard Brånemark will moderate a workshop in Ukraine on 21 September, focusing on war-related amputee care. The workshop gathers some of the world's most prominent specialists and is supported by several ministries in Ukraine.

read more
14 September 2023
Regulatory

Integrum initiates a strategic review process to accelerate growth

Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that its Board of Directors has initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™ Implant System.

read more
11 September 2023

Integrum announces organizational changes and appoints Alex Winber as VP Sales and Marketing in the US

Mölndal, Sweden, September 11, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has appointed Alex Winber as Vice President Sales and Marketing with full focus on the US. The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.

read more
8 September 2023

Integrum receives reimbursement code for Axor II™

Mölndal, Sweden, September 08, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that The Centers for Medicare and Medicaid Services (CMS) have granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code, which is expected to take effect in October, is connected to a set reimbursement that will help to drive growth in the US.

read more
31 August 2023
Regulatory

Integrum reports highest quarterly sales revenue ever

FIRST QUARTER 2023/24 (MAY – JULY) · Net sales amounted to SEK 20.4 (17.2) million, which is an increase of 18% compared with the corresponding period last year. · Operating profit amounted to SEK -2.9 (0.4) million. Excluding one-off costs the operating profit is SEK 0.5 million. The largest such cost is severance pay regarding the change of leadership in the US. · Profit/loss after tax amounted to SEK -2.9 (-0.6) million, which resulted in earnings per share of SEK -0.1 (-0.03). · Cash flow from operating activities before changes in working capital amounted to SEK -2.6 (-0.3) million. · Liquid assets as of 31 July 2023 amounted to SEK 29.9 (57.3) million. Although Q1 saw a negative cash flow overall, the largest effect comes from increase in receivables, and with SEK 23,3 million in total AR, it reinforces the management position that the business has the liquid assets needed for further growth. · Currency fluctuations continue to affect the company operating profit. During the quarter the operating result was positively affected with 2,4 MSEK from currency effect on intragroup Accounts receivables (AR). Significant events in the quarter · Integrum appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan. Jeff has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. He started his position in July. · In May, Scott Flora was appointed adjunct board member. He brings extensive global business competence in orthopaedics. · The academic evaluation of a scientific paper on sensory feedback using the OPRA[TM] Implant System together with e-OPRA[TM] confirmed that no misconduct had been committed. · Integrum announced that Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago, US – has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.

read more
13 July 2023

Integrum’s technology using AI gives an above-elbow amputee unprecedented control of every finger in a bionic hand

Mölndal, Sweden, July 13, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the first case study of a person with above-elbow amputation obtaining unprecedented control of every finger in a bionic hand has been published in Science Translational Medicine. By combining Integrum’s OPRA™ Implant System and e-OPRA™ Implant System with revolutionary surgical and engineering advancements and AI algorithms, the user’s intentions were translated into the movement of the bionic fingers.

read more
16 June 2023

Integrum appoints Jeffrey S. Zanni as President, U.S.

Mölndal, Sweden, June 16, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan, who has decided to resign from his position. 

read more
8 June 2023
Regulatory

Shirley Ryan AbilityLab receives a USD 8.7 million NIH grant to fund clinical trials including Integrum’s e-OPRA Implant System

Mölndal, Sweden, June 8, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago, US – has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). The grant will be used to fund two clinical trials evaluating the function of Integrum’s e-OPRA[TM] Implant System. It is anticipated that Integrum will receive  up to USD 1.3 million during the program to support the study activities.

read more
8 June 2023
Regulatory

Year End Report May 2022 – April 2023: CONTINUING TO BUILD THE COMPANY

read more
1 June 2023

Integrum and collaboration partners receive SEK 3.2 million in research grant for textile-based HOPE project

Mölndal, Sweden, June 1, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the Knowledge Foundation (Stiftelsen för Kunskap och Kompetensutveckling) has granted SEK 3.2 million to the textile-based research project HOPE, where Integrum collaborates with the University of Borås, Bola AB and Daralabs AB. Integrum’s aim in this project is to further develop and expand the company’s Neuromotos system business.

read more
1 June 2023

Integrum invites to Open House Event to celebrate its 25-year anniversary

Mölndal, Sweden – June 1, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host an Open House Event on June 15 to inaugurate the company’s new headquarters at GoCO Health Innovation City and celebrate its 25th anniversary.  

read more
29 May 2023

Integrum appoints Supply Chain Manager

Mölndal, Sweden – May 29, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Katarina Oderland as new Supply Chain Manager. Katarina Oderland will join the company on 14 August 2023 and will be part of the management team.

read more
11 May 2023

Integrum announces the appointment of Scott Flora as adjunct board membe

Mölndal, Sweden – May 11, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company’s position as a leader of osseointegrated implant systems.

read more
9 May 2023

Integrum's CEO Rickard Brånemark holds the keynote lecture at ISPO 2023 in Germany

Mölndal, Sweden, May 09, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the company's CEO Rickard Brånemark will hold the keynote lecture on Bionic Limb Reconstructions, at the International Society for Prosthetics and Orthotics, ISPO 2023 in Hanover, Germany.

read more
3 May 2023

Integrum moves into new head office at GoCo Health Innovation Cit

Mölndal, Sweden – May 3, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has moved into its new office at the GoCo House, in the center of GoCo Health Innovation City, as the company continues its expansion.

read more
2 May 2023

Integrum announces appointment of Jörgen Svanström as interim CFO

Mölndal, Sweden – May 2, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Jörgen Svanström as interim Chief Finance Officer.

read more
28 April 2023

Integrum is granted patent approval for its OPRA™ Implant System in Australia

Mölndal, Sweden, April 27[th], 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in Australia describing components and design features of the OPRA™ Implant System. The patent period extends until 2037.

read more
2 March 2023

Integrum named to Fast Company’s 2023 List of the World’s Most Innovative Companies

Mölndal, Sweden – March 2[nd] 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies (https://www.fastcompany.com/most-innovative-companies/list) for 2023.

read more
2 March 2023

Integrum receives MDR certificate for the OPRA Implant System

Mölndal, Sweden, March 2[nd], 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the company has received an EU Medical Device Regulation (MDR) certificate for the OPRA[TM] Implant System. With this, the company is provided continued freedom of operation to commercialize its products within the EU.

read more
28 May 2021

Integrum hosted a technical workshop on the clinical advantages of the OPRA™ Implant System and how it helps patients lead more active lives at the AAOP (American Academy of Orthotists and Prosthetists) annual meeting and scientific symposium

May 4th – 7th the AAOP held its annual meeting and scientific symposium (virtually) in New Orleans, Louisiana. During the meeting, Integrum hosted a technical workshop for prosthetists and orthotists from around the world. Presenters during the workshop were Kurt Collier, Certified Prosthetist and VP of Prosthetics at Integrum, Kevin Symms, Certified Orthotist, and amputee […]

read more
28 May 2021

Integrum’s industrial PhD student Alexander Thesleff successfully defends his doctoral thesis “Neuromusculoskeletal interfacing of lower limb prostheses“ at Chalmers University of Technology, Gothenburg, Sweden

On May 27th, Alexander Thesleff received his Ph.D. from the Department of Electrical Engineering, Chalmers University for his research regarding the connection of a leg prosthesis with the skeleton, muscles, and the nerves. Alexander received an Industrial Ph.D. based on his research performed in collaboration with Chalmers and Integrum, for his investigation of the challenges […]

read more
17 May 2021

Rickard Brånemark interviewed by Innovativa Företag (Innovative Companies)

In their latest issue, Innovativa Företag, a magazine focusing on the most innovative companies in Sweden, interviewed Professor Rickard Brånemark. The magazine is published online, and is distributed in print with Svenska Dagbladet, which is Sweden’s 3rd largest daily newspaper. It reaches approximately half a million readers. During the interview, Professor Brånemark describes the journey […]

read more
16 May 2021

Per-Ingvar Brånemark, honored by the inauguration of Global Osseointegration Day

  May 3rd, 2021, marks the first Global Osseointegration Day, a day which posthumously honors Professor Per-Ingvar Brånemark, who is regarded around the world as the “father” of osseointegration. Global Osseointegration Day will take place every year, on May 3rd, Professor Per-Ingvar Brånemark’s birthday. Read about the event Global Osseointegration Day Professor Brånemark’s pioneering work […]

read more
16 May 2021

Per-Ingvar Brånemark, honored by the inauguration of Global Osseointegration Day (Deutsch)

  May 3rd, 2021, marks the first Global Osseointegration Day, a day which posthumously honors Professor Per-Ingvar Brånemark, who is regarded around the world as the “father” of osseointegration. Global Osseointegration Day will take place every year, on May 3rd, Professor Per-Ingvar Brånemark’s birthday. Read about the event Global Osseointegration Day Professor Brånemark’s pioneering work […]

read more
25 Feb 2021

Die BG Klinik Tübingen unter den ersten in Deutschland, die Patient/innen mit amputiertem Daumen mit dem OPRA™ Implantatsystem von Integrum behandelt

Am 27. Januar behandelte die Abteilung für Hand-, Plastische, Rekonstruktive und Brandwunden-Chirurgie des BG-Trauma Centers in Tübingen ihre ersten Patienten mit dem OPRA™ -Implantatsystem und war eines der ersten Krankenhäuser in Deutschland, das diese Technologie zur Behandlung von Patient/innen mit amputiertem Daumen zum Einsatz brachte. Die Abteilung ist integraler Bestandteil des BG Trauma Centers und […]

read more
20 Oct 2020

Biostock Studio: Integrum has a monopoly situation in the U.S. market

Swedish Integrum AB has developed the only FDA approved method for treating amputees with bone-anchored prostheses. In an interview with Biostock, Rickard Brånemark, founder and Chairman of the Board at Integrum AB, describes the head start that the company has as being alone in the U.S. market for the next 3-5 years; a market which […]

read more
14 Oct 2020

In Conversation With Biostock:- On Integrum's Leading Position in the Bone-Anchored Prosthesis Industry

In an article published on October 13th, 2020, Biostock interviewed James Sheridan, Head of Sales and Marketing, EMEA, APAC at Integrum AB, and Patrick Treacy, CEO at Onkos Surgical. The article outlines Integrum’s leading position in the bone-anchored prosthetics market, the commercial breakthrough through its framework agreement with the US Military, the Pre-market Approval application […]

read more
20 Aug 2020

Integrum’s Co-Founder and Chairman of the Board, Professor Rickard Brånemark, interviewed by Biostock

In an article titled ‚Integrum awaits an important milestone on the road to commercial breakthrough‚ published August 2020, Biostock interviews Professor Rickard Brånemark, co-founder and Chairman of the Board.  The interview touches upon the history of Integrum with the discovery of Osseointegration and dental implant technology. It visits several milestones for the company, such as […]

read more
18 Aug 2020

Integrum exhibiting at the Amputee Coalition 2020 National Conference

Join us on August 19-22 at the Amputee Coalition 2020 National Conference!  Integrum is happy to announce our participation at the Amputee Coalition virtual 2020 National Conference held between August 19-22.   The American Amputee Coalition is a non-profit organization dedicated to enhancing the quality of life for amputees and their families through support, education about […]

read more
27 Jul 2020

Integrum’s e-OPRA™ Implant System is Restoring Touch in Prosthetic Arms

Advances in robotics are paving the way towards prostheses with functionalities similar to their biological counterparts. While the state-of-the-art prostheses are now capable of mimicking fine movements and grips, the level of intuitive control and sensory feedback individuals with amputation have with their prostheses are still primitive.   Researchers recently published the capabilities of our osseointegrated […]

read more
14 Jul 2020

Clinical Research Quantifies Loads for Osseointegrated Lower Limb Prostheses

Prosthesis acceptance is a major determinant of people’s quality of life after amputation. Along with factors such as phantom limb pain, misaligned expectations for prosthesis, psychological adjustment and functionality, prosthetic socket issues are a primary reason for prosthesis rejection. Compression and friction forces imposed by the prosthetic socket on the skin of the residual limb […]

read more
09 Jul 2020

Reuters features Integrum's e-OPRA™ Implant System

Reuters features Integrum’s e-OPRA™ Implant System The e-OPRA™ Implant System is one of the most advanced prosthetic systems in the world with intuitive control and sensory feedback. The technology is developed upon the OPRA™ Implant System– our bone-anchored prostheses system based on osseointegration.  The clinical report demonstrating the long-term performance of the e-OPRA™ Implant system […]

read more
12 Jun 2020

University Medical Center Groningen at the Forefront of Translating Phantom Limb Pain Research into Clinical Care with Neuromotus™

The University Medical Center Groningen   As one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands, the University Medical Center Groningen (UMCG) focuses on care, education, training, and research. The UMCG not only provides patient-centered care but also aims to conduct revolutionary scientific and educational research on healthy ageing to build the […]

read more
04 Jun 2020

Bo Håkansson, a pioneer in osseointegration research, rewarded honorary doctorate at the Sahlgrenska Academy.

Bo Håkansson is a professor of Electrical Engineering at the Chalmers University of Technology. He is the pioneering researcher in bone-anchored hearing implants. His work resulted in the translation and development of commercially available osseointegrated hearing aids that have positively impacted the lives of several thousands of people worldwide. The appointment by the Board of […]

read more
29 May 2020

OPRA™ Implant System – Transforming the World of Prosthetics

ABC 12 News features Osseointegration with the OPRA™ Implant System ABC 12 News, a news channel in Michigan, featured the OPRA™ Implant System and the technology of Osseointegration on their segment HealthSource. Watch the video here. They interviewed Munya Mahiya, who recently shared his story on WMC5 Action News, highlighting Osseointegration and the OPRA™ Implant […]

read more
25 May 2020

Integrum and Onkos Surgical hold second educational seminar on Osseointegration

Integrum and Onkos Surgical hosted their second online educational symposium recently on the surgical and prosthetic technologies used with the OPRA™ Implant System. The symposium was attended by 30 participants from 15 institutions. We thank all the participants and look forward to continued collaborative work The collaboration between Integrum and Onkos Surgical is focused on […]

read more
18 May 2020

Job Opening: Head of Sales and Marketing EMEA

Integrum AB is seeking to hire an executive to lead its Sales and Marketing organization.  The individual will oversee Integrum’s product portfolio:  OPRATM Implant System – a revolutionary surgical technology that allows amputees to be set free from the confines of a traditional socket-based prosthesis and Neuromotus – an innovative solution for the treatment of […]

read more
14 May 2020

e-OPRA™ recipient shares his perspective on TV4 news

The Ideal Replacement for a Biological Hand The conclusions of the clinical study on the efficacy and performance of the e-OPRA™ system was published recently in the New England Journal of Medicine. One of the recipients of the e-OPRA™ system. Rickard Normark, shared his perspective on  TV 4, a Swedish news channel. Watch the interview […]

read more
11 May 2020

A Near Bionic Prosthetic-The OPRA™ Implant System

A Near Bionic Prosthetic Munya Mahiya, a UC Berkeley Alumnus and a wheelchair basketball player for the Golden State Road Warriors, has recently shared his story and postoperative experience with the OPRA™ Implant System on WMC Action News 5. The OPRA Implant system is a bone-anchored prosthesis system that allows the prosthesis to be skeletally […]

read more
21 Apr 2020

Onkos Surgical & Integrum Co-Hosts Educational Session On Osseointegration

With the spread of the pandemic and consequent restrictions on traveling the American Academy of Orthopaedic Surgeons Annual Meet 2020 in Florida was canceled where Integrum and Onkos Surgical had planned their inaugural presentation after the partnership announcement in January 2020. The collaboration between Integrum and Onkos Surgical is focused on expanding the US market […]

read more
17 Apr 2020

Dr.Max Ortiz Catalan receives the Chalmers Foundation Award 2020

Dr. Max Ortiz Catalan receives the Chalmers Foundation Award for 2020 for his work on natural control of prostheses through osseointegrated implants. CHALMERS FOUNDATION The Foundation’s motivation for the award is as follows: “The Chalmers Foundation was formed in 1994, with the task of supporting Chalmers to carry out research and education at a high […]

read more
25 Feb 2020

Dr. Brånemark to present at University of Maryland

Dr.Brånemark will present a Seminal Research lecture on Osseointegration at the University of Maryland on 28th February.  He will share the groundbreaking advances within osseointegration and limb restoration as well as the latest research. Despite the advances in prosthesis and sockets, there is a high rejection rate of socket prosthesis among people with amputation. For […]

read more
20 Feb 2020

Meilensteine in der Amputationsmedizin an der Universitätsmedizin Göttingen

Die Universitätsmedizin Göttingen (UMG) befindet sich mit der Durchführung ihrer ersten TMR-Operation (Targeted Muscle Reinnervation) im letzten Jahr an vorderster Front der orthopädischen Chirurgie in Deutschland. Osseointegration für amputierte Menschen bezieht sich auf das direkte Verankern der Prothese über den Knochen. Diese Behandlung wird zurzeit zu einer allgemein akzeptablen und vorteilhaften Alternative für amputierte Menschen, […]

read more
02 Dec 2019

Alfred Hospital-Establishing Holistic Amputee Care Management in Australia

In  October 2019, Alfred Hospital conducted their fourth workshop on Osseointegration for Bone Anchored prosthesis with the OPRA Implant system and Target Muscle Reinnervation (TMR) at the Regional Medical Australian and New Zealand Society (RMANZ). Pioneering Osseointegration in Australia The Alfred Hospital is the largest and most active Trauma Service in Australasia. They treat over […]

read more
25 Nov 2019

Henry Wallman 2019 Award Cermony

  In June 2019, the Stiftelsen Medicin och Teknik at Chalmers announced Dr. Rickard Brånemark, Dr. Max Ortiz Catalan and Kerstin Hagberg as the receipients of the 2019 Henry Wallman Award. The award recognizes their work within osseointegrated neural controlled prosthetics (e-OPRA). Our press release published 26 June 2019 describes more about the the work that […]

read more
31 Oct 2019

Event Recap: Osseointegration at 2019 NEAAOP Conference 

Developments in Osseointegration The benefits of osseointegration for both upper and lower limb amputees has been well recognized and documented in numerous peer reviewed clinical studies.  In June of 2015 the FDA provided an HDE approval (Humanitarian Device Exception) for use of the OPRA System (Osseointegrated Prosthesis for Rehabilitation of Amputees) for transfemoral amputees.  Work […]

read more
09 Oct 2019

Inside Walter Reed: The Future of Prosthetics

NBC4 News aired a segment on ‚Inside Walter Reed:The Future of Prosthetics‚ on October 8th‘ 2019. The program features the OPRA Implant System from Integrum. News4’s Doreen Gentzler talks about her visit to Walter Reed National Military Medical Center at Bethesda, Washington. During the visit, she learned about the clinical trial evaluating Osseointegration as a […]

read more
01 Oct 2019

Upcoming Event: Dr. Ortiz holding Keynote Lecture at ISPO World Congress 2019

International Society for Prosthetics and Orthotics (ISPO) Kobe, Hyogo Japan 5-8th October 2019 Kyobe, Hyogo Japan is hosting the 17th International Society for Prosthetics and Orthotics (ISPO) World Congress between 5-8th October 2019.   ISPO is a global non-profit organization working towards improving the quality of life for people with reduced mobility. This is done by […]

read more
23 Sep 2019

Integrum on 'Voice of Industry'-ORTHOWORLD

ORTHOWORLD® is a provider of strategic intelligence focussed on the global orthopaedic market. Their mission is to help orthopaedic companies and individuals improve their performance. They featured an interview with Magnus René on the success of the OPRA™ osseointegrated prosthetic implant system. Magnus René is the former President and CEO of Arcam and member of […]

read more
15 Sep 2019

Upcoming Event: OPRA Insight Forum Series: Chapter Orlando

The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the limb loss community about Osseointegration. The forums are designed to provide a broad perspective on Osseointegration and specifically the OPRA Implant System. A review of the acceptance criteria for consideration, brief […]

read more
10 Sep 2019

Upcoming Event: OPRA™ Insight Forum Series: Chapter Boston

The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the limb loss community about Osseointegration. The forums are designed to provide a broad perspective on Osseointegration and specifically the OPRA Implant System. A review of the acceptance criteria for consideration, brief […]

read more
07 Sep 2019

Patient completes 20 year check up with OPRA™ Implant System

Erik Ax, 79 years old, is one of the earliest recipients of the OPRA™ Implant System. Erik is an above-knee amputee who was having several problems with his prosthetic socket.As a result, he sought out Integrum to receive an osseointegrated bone-anchored prosthesis. He had his osseointegration surgery in 1999 and is now having his implant […]

read more
06 Sep 2019

Upcoming Event: Clinical Assessment for Osseointegration Patients in London, UK

London International Patient Services (LIPS) is hosting a clinical assessment session with Mr.Culpan and Prof. Brånemark on Sept 13, 2019. At this session, Prosthesists or Orthosists with patients interested in Osseointegration and amputees will have the opportunity to get a clinical assessement for osseointegration with the OPRA Implant System. The session will be held at […]

read more
03 Sep 2019

Upcoming Event: 20th Annual Meeting of ISOLS, 2019

Athens, Greece will be hosting the 20th Annual Meeting of International Society of Limb Salvage (ISOLS). The ISOLS is a platform where experts in the field of musculoskeletal oncology and limb salvage techniques come together to promote intellectual exchange in research, surgical techniques, education and clinical practice in the discipline. Dr. Rickard Brånemark will be […]

read more
27 Aug 2019

Celebrating 10 years of Osseointegration in Chile.   Pioneering Osseointegration in Latin America. 

On Aug 20th,  Hospital del Trabajador-Chile hosted the Congress of Osseointegration 2019 in commemoration of 10 years of Osseointegration in Chile. Hospital del Trabajador are the pioneers in the region and the only center providing osseointegration in Latin America.   Over 90 participants from a mixed population of surgeons, healthcare providers, physiotherapists, occupational therapists and amputees […]

read more
23 Aug 2019

INTEGRUM TO INAUGURATE OPRA INSIGHT FORUM SERIES

In conjunction with the company’s ongoing expansion in the US, Integrum will inaugurate the OPRA Insight Forum Series with its first chapter in Charlotte, North Carolina, USA on August 27TH, 2019. The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the […]

read more
15 Aug 2019

Celebrating 10 years of Osseointegration in Chile . Pioneering Osseointegration in Latin America.

We are glad to celebrate 10 years of experience in osseointegration with our collaboration team in Chile during the Congress of Osseointegration in Hospital del Trabajador- Chile, which will be held on August 20, 2019. The convention will provide healthcare providers, patients and the community with information on osseointegration with the OPRA Implant System, its […]

read more
10 Aug 2019

Congratulations to UCSF on being ranked among Best Hospitals in USA.

US News recognizes UCSF Medical Center as one the leading hospitals in the country with 10 departments in the top 10 centers nationwide in their U.S. News & World Report’s 2019-2020. The orthopaedics department has been ranked 4th nationwide. Integrum congratulates UCSF on their continued recognition as one of the most prestigious hospitals in the […]

read more
10 Jul 2019

Best Wishes for the Summer Holidays!

read more
02 Jul 2019

Congratulations Dr Enzo Mastinu!

We are proud to announce that our colleague Enzo Mastinu has successfully defended his PhD thesis, “Towards clinically viable neuromuscular control of bone-anchored prosthetic arms with sensory feedback” at Chalmers University of Technology.   Dr. Mastinu has pursued his PhD in a joint collaboration between Integrum AB and Chalmers University of Technology, developing an embedded system for intuitive control of a […]

read more
14 Jun 2019

Meet Integrum at FEESH,17-21st of June in Berlin, Germany!

We are pleased to announce that Integrum will participate at the FEESH meeting 17-21 st of June 2019 in Berlin, Germany. Integrum will be present in the booth at Pohlig GmbH. During the meeting the technology of osseintegration for finger/thumb and arms will be shown. In January 2019 a new study was published to be […]

read more
16 May 2019

COME VISIT US AT VITALIS 2019 Integrum will be presenting at Vitalis (Booth B06:71)

Vitalis is the largest eHealth event in Scandinavia. The event is visited by many key individuals, organizations and companies operating in the Nordic countries. A growing number of delegates from outside the Nordics are also attending.

read more
15 Sep 2018

Prof R Brånemark is a selected speaker and will give a lecture at Klinikum der Universität München, Germany, 18th of September.

Next week, 18th of September 2018, Prof Rickard Brånemark who is a selected speaker at the Klinikum der Universität München, will give a lecture on Osseointegrated Implants in prosthetic extremity reconstructions- Interfacing in the 21st century. Flyer_SL_Branemark_2018-07-11

read more
24 Aug 2018

Rick Cicero, transfemoral and transhumeral amputee and recipient of Integrum’s OPRA Implant System.

  Rick Cicero KVOA News 4 Tucson AZ July 16th, 2018   Rick Cicero, transfemoral and transhumeral amputee and recipient of Integrum’s OPRA system at both levels shares his life changing experiences on the local news channel in Tucson, Arizona during the Annual Amputee Coalition Conference.  He is providing a presentation to the rehabilitation specialist […]

read more
17 Aug 2018

Association of Orthotist and Prosthetist of America

The 2018 National Assembly will be held September 26-29 in Vancouver, BC, Canada—An expected 2,500 attendees from over 40 different countries are expected to attend.  A larger booth, #1212, with two OPRA patients present will increase our presence and help to strengthen the brand.  Lastly, Dr. Branemark’s presentation during the Future Possibilities in Amputation Surgery […]

read more
06 May 2018

Meet us at 2nd International Symposium on Innovations in Amputation Surgery and Prosthetic Technologies meeting (IASPT) May 9-12th 2018 in Vienna!

 We are pleased to announce that Integrum will participate at the  2nd International Symposium on Innovations in Amputation Surgery and Prosthetic Technologies meeting (IASPT) May 9-12th 2018 in Vienna, Austria. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in our booth.  […]

read more
04 May 2018

Meet us at EMSOS 9-11 th of May in Amsterdam!

Meet us at EMSOS 9-11 th of May in Amsterdam! We are pleased to announce that Integrum will participate at the EMSOS (European Musculo-Skeletal Oncology Society) meeting 2018 May 10-11 in Amsterdam, Netherlands. Please visit us and meet with some of Integrum’s product users and Integrum staff. You are very welcome to find us in booth 2.

read more
26 Apr 2018

OPRA™ bone anchored prosthesis now available in London

The unique OPRA™ Implant System from Integrum, who improves the quality of life for patients by eliminating the need for a conventional socket prosthesis, is now provided by London International Patient Services (LIPS) your connection to London’s top consultants. For more information please click on this link: IntegrumLIPS    

read more
17 Apr 2018

Meet us at the OTWorld 15th-18th of May 2018 in Leipzig!

We are pleased to announce that Integrum will participate at the OTWorld 2018 May March 15-18th in Leipzig. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in booth D01b Hall 5. During the OTWorld meeting Integrum will also invite for […]

read more
09 Feb 2018

Meet us at the AAOS 2018 Annual Meeting!

We are pleased to announce that Integrum will participate at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting March 6-10 in New Orleans, Louisiana, USA. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in booth 1013. Meeting Location: […]

read more
14 Dec 2017

US Army Soldiers are fitted with Integrum’s OPRA Implant System

Integrums collaboration with the US Department of Defense is showing good progress and several patients have started the rehabilitation phase. The osseointegration program is led by the work of Navy Commander (Dr.) Jonathan Forsberg and Army Lieutenant colonel (Dr.) Kyle Potter. Please click on the link to experience some of the great achievements https://www.youtube.com/watch?v=eS4O99lLgrY&feature=youtu.be   […]

read more
24 Nov 2017

Integrum is included in the magazine inMotion for the limb loss community

The award-winning publication inMotion is written by healthcare professionals, leaders in the limb loss community and those affected by limb loss. Integrum is proud to be part in the inMotion magazine and hope that more individuals with limb loss will recognize the benefits of bone anchored prosthesis. Please klick on the link for the full […]

read more
20 Nov 2017

Integrum was recognized by the French President Emmanuel Macron and Stefan Löfven

Integrum had the honor to meet the President of France and the Swedish Prime Minister this Friday evening. Very honorable that Integrum is recognized at this event and we hope that it will enable us to reach out to more people in France. Check out the last 6 minutes of the video link: https://www.facebook.com/EmmanuelMacron/videos/2062784580620784/

read more
07 Jul 2017

2-day instructional course in osseointegration

Save the date 15-16th Nov 2017  Integrum invites medical professionals to participate in a 2-day instructional course for the OPRA Implant System for thumb/finger, humerus and femur in November 2017. The course will give the professionals an introduction to osseointegration and the OPRA Implant System. The attendees will have the opportunity to meet with experienced […]

read more
04 Jun 2017

The US Department of Defense offers amputees a revolutionary new option in prosthesis

<!–Notes ACF –> Integrums collaboration with the US Department of Defense has good progress and some patients have already initiated the treatment using Integrums OPRA Implant System. The osseointegration program at Walter Reed Walter Reed National Military Medical Center (WRNMMC) began in 2016. The osseointegration program is led by the work of Navy Cmdr. (Dr.) […]

read more
23 May 2017

Integrum's first delivery to Ottobock in the United States

The first delivery of Integrum prosthetic components to Ottobock has been carried out in the United States. This marks the start of Integrum’s collaboration with Ottobock Healthcare. The order represents a strategically important milestone since Ottobock can start to sell & market Integrum’s products on the US market. „We are very proud to collaborate with […]

read more
15 May 2017

Nasdaq Stockholm welcomes Integrum to First North

Nasdaq (Nasdaq: NDAQ) announces that the trading in Integrum AB’s shares (short name: INTEG B) commenced today on Nasdaq First North in Stockholm. Please read more here

read more
02 May 2017

Winner of the Blatchford Award 2017

Integrum collaborators have been awarded for outstanding record of innovative achievement in the field of prosthetics and/or orthotics. The Blatchford Award 2017 has been presented to the multidisciplinary team of surgeons, physiotherapists, occupational therapists, and prosthetists from Sahlgrenska University Hospital (SUH), as well as researchers from Chalmers University of Technology (CTH) and University of Gothenburg […]

read more
27 Apr 2017

Nasdaq First North IPO May 15th

Integrum has talking the steps to be a listed company on Nasdaq First North. We have reached several milestones in the listing process and the date is set to be May 15 as the introduction date. This will enable several advantages for Integrum and we will be able to provide additional resources for development, marketing […]

read more
13 Mar 2017

Integrum and Ottobock Partner for the Benefit of Amputees

Integrum has entered a collaboration with Ottobock in the field of osseointegration regarding distribution of prosthetic connection elements related to Integrum’s OPRA implant system. Integrum is thrilled to collaborate with Ottobock, the market leader in prosthetics, to distribute Integrum’s prosthetic components in the US. This is a major step forward in developing Integrums presence in […]

read more
05 Feb 2017

Integrum surgical course in San Diego, March 12-13, 2017

The University of California San Francisco (UCSF) and the Orthopaedic Surgical Osseointegration Society (OSOS) are arranging the 7th international conference about Advances in Orthopaedic Osseointegration. Several Integrum co-workers will participate and share some of our latest developments. Integrum will arrange a surgical course at the conference. Please read more here  

read more
09 Jan 2017

A new stronger OPRA Implant System is launched

Integrum is introducing the OPRA Implant System Platform G to be used for transfemoral patients. The new platform is CE labeled and approved by the FDA and will be available in January 2017. The OPRA Implant System Platform G improves the mechanical performance of the system, simplifies the surgical procedure and enhances osseointegration. Please contact […]

read more
02 Dec 2016

A revolutionary phantom limb pain treatment

Neuromotus is a revolutionizing technology to relieve Phantom Limb Pain. The technology has been proven in a clinical trial with good results. The results have recently been published in the medical journal The Lancet. The technology is in the final stage of development. Please read more at our new product website Neuromotus.se and sign up […]

read more
08 Nov 2016

UCSF Medical Center performs Osseointegration crowdfunding campaign

UCSF Medical Center is planning to treat several Transfemural (above the knee) patients on a yearly basis. Apart from hospital expenses, patients traveling from across the nation will have to find resources to cover the cost of lodging and travel in order to have the first clinical screening, as well as surgery and aftercare. UCSF […]

read more
02 Nov 2016

Integrum’s Research Director, Dr. Max Ortiz Catalán is the winner of the 14th Annual Delsys Prize

Dr. Max Ortiz Catalán winning proposal, titled “Myoelectric pattern recognition and augmented reality for the treatment of Phantom Limb Pain”, was selected from a field of 134 entries from 29 countries. The entries represented a remarkably broad range of interests in diverse areas as Biomechanics, Exercise Physiology, Signal Processing, Facial EMG, Robotics, Rehabilitation, and various […]

read more
15 Oct 2016

Sweden wins medal in the Cybathlon competition, “cyborg Olympics”, at the Swiss Arena in Zürich

The first recipient of our osseointegration and neural control technology competed on 8 October in the Cybathlon, an event aimed at pushing the technological boundaries to reduce disability. More than 8,000 spectators and 700 journalists covered this initial event. Despite being the only participant with an above-elbow amputation, a disadvantage when competing against below-elbow-amputees, the […]

read more
04 May 2016

The first US surgery has successfully been performed at UCSF

UCSF Medical Center in San Francisco is the first U.S. center to proceed with an OPRA program. This unique program gives amputees new hope for better prosthesis. The historic first U.S. surgery with the Integrum OPRA System took place last week. The patient receiving the implant is a 54-year-old man who lost most of his right leg due to […]

read more
17 Apr 2016

Kerstin Hagberg in the latest issue of “Fysioterapi”

Physiotherapist Kerstin Hagberg, associate professor at the Centre of Orthopaedic Osseointegration (COO) at Sahlgrenska University Hospital, is in the latest issue of the Swedish magazine “Fysioterapi”. In the article, you can read about Kerstin’s work and how the OPRA Implant system has change the life for a young Swedish man. Read the article here (Swedish)

read more
05 Apr 2016

Dr. Brånemark featured speaker at IAA Conference

The founder of Integrum, Dr. Rickard Brånemark , is one of the featured speakers at the 30th Annual meeting of the International Anaplastology Association to be held June 1-4, 2016 in Dallas/Fort Worth, Texas. Take the opportunity to listen to Dr. Brånemark and his presentation “Osseointegration for Orthopedic Applications” on 2 June at 2.05 pm. Read […]

read more
02 Jan 2016

News report

ABC 7 News have done a news report about the OPRA Implant System that is currently being tested at the University of California, San Francisco. The report can be read here

read more
08 Oct 2015

Orthotic and Prosthetic Innovation & Technology Symposium

Dr. Rickard Brånemark, founder of Integrum, is one of the featured speakers at the 6th Orthotic and Prosthetic Innovation & Technology Symposium which is held on the 6th of November in the Milberry Union Event & Meeting Center in San Francisco. You can read more about the symposium here

read more
24 Sep 2015

Article in Göteborgs-Posten

The Swedish Newspaper Göteborgs-Posten, the biggest daily morning paper in the west of Sweden, published an article about Integrum. The article describes how Integrum will enter the US market and also briefly describes conventional products compared to bone anchored prostheses. The article can be read here (in Swedish)

read more
16 Sep 2015

Article in Dagens Industri

The Swedish newspaper Dagens industri, Scandinavia’s largest business newspaper, has published an article about Integrum. The article relates to Integrum being the first company in the world with bone anchored prosthesis to be approved by the FDA for use in the U.S. The article can be read here (in Swedish)

read more
16 Jul 2015

The OPRA Implant System is FDA approved

The U.S. Food and Drug Administration (FDA) has of today, July 16th 2015, announced that the humanitarian device exemption (HDE) for Integrum´s OPRA Implant System is approved. The approval provides an unprecedented opportunity to improve the life for several thousands of individuals living with limb loss in the United States. Integrum is the first company […]

read more
30 Jun 2015

Swedish Medtech week

Integrum was part of the Swedish Medtech week hosted by the Association for Medical Technology in Sweden. Integrum presented the company and demonstrated some of the latest research. This was an event for national and regional officials and politicians aiming to raise awareness and create a conversation about medical technology. You can read more about […]

read more
18 Jun 2015

Conference of the International Graphonomics Society

Dr. Max Ortiz Catalan from Integrum will give a keynote speech at the 17th Conference of the International Graphonomics Society on Monday 22th of June. You can read more about it here 

read more
15 Jun 2015

A big thank you

A big thank you to everyone who participated in the Prosthetic course last week. We appreciate the feedback and it was nice to see everyone.

read more
27 May 2015

the Shanghai Symposium on Neural-Machine Interfacing

Dr. Max Ortiz Catalan from Integrum will be giving a talk at the Shanghai Symposium on Neural-Machine Interfacing on June 16th. The talk will be about his neuromuscular interface that allows for mind controlled prosthetics that is based on the OPRA Implant System

read more
11 May 2015

The Centre of Advanced Reconstruction of Extremities

The Centre of Advanced Reconstruction of Extremities (C.A.R.E.) at Sahlgrenska University Hospital is inaugurated on Friday the 22th of May. Integrum will be present as will some of the patients using the OPRA system.

read more
25 Mar 2015

Meet us at AAOS Annual Meeting!

We are pleased to announce that Integrum will participate at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas, March 25-27, 2015. You are very welcome to find us in booth number 664. See more here.

read more
18 Mar 2015

Göteborgs-Posten

The Swedish newspaper Göteborgs-Posten, has a piece on a patient treated with the OPRA Implant System. The treatment has helped the patient return to his job as an optician and has improved his quality of life. The piece can be read here (in Swedish).

read more
09 Feb 2015

Presentation

CEO of Integrum and associate professor at Sahlgrenska University Hospital, Dr. Rickard Brånemark and Dr. Max Ortiz Catalan presented their work in mind-controlled prosthetics to the Swedish Minister of Enterprise, Mikael Damberg. The Swedish news paper, Dagens Industri, did a report that can be read here (In Swedish, requires subscription, but a free try-out period is available)

read more
09 Jan 2015

Watch the TEDxGöteborg-talk

In November, Dr. Max Ortiz Catalan from Integrum gave a talk at TEDxGöteborg about his mind controlled prosthetics that are based on the OPRA Implant System. The talk can be watched here

read more
16 Dec 2014

Watch the Spanish talkshow

Dr. Max Ortiz Catalan from Integrum participated in the Spanish talkshow El Hormiguero together with 2 patients. The show can be streamed here (in Spanish). Integrums effort into mind controlled prosthetics is considered the 7th most important research project by the Swedish Dagens Medicin. Their report can be read here (in Swedish).

read more
09 Dec 2014

Participating in the Spanish talkshow El Hormiguero

Dr. Max Ortiz Catalan from Integrum will participate in the Spanish talkshow El Hormiguero together with Magnus Niska, who is the first patient using OPRA with neuromuscular electrodes and Irene Villa, who is a bilateral amputee using the OPRA implant system. The program is broadcasted on Spanish Antena 3 TV the 10th of December at […]

read more
17 Nov 2014

Interview with Magnus Niska

Magnus Niska, the first patient using OPRA with neuromuscular electrodes, was interviewed in the Swedish talkshow „Malou efter tio“. The interview can be seen here (in Swedish).

read more
13 Nov 2014

TEDxGöteborg

Dr. Max Ortiz Catalan from Integrum will give a talk at TEDxGöteborg the 18th of November about his mind controlled prosthetics that are based on the OPRA implant system. More information about the talk can be found here

read more
31 Oct 2014

Interview with Dr. Rickard Brånemark

CEO of Integrum and associate professor at Sahlgrenska University Hospital, Dr. Rickard Brånemark, is interviewed by Reuters about the mind-controlled prosthetic arm, that has been made possible with the next generation of the OPRA system. The report can be seen here.

read more
08 Oct 2014

The first patient using OPRA™ with implanted neuromuscular interfaces is revealed.

The future for the OPRA™ system is presented today, as the first patient using OPRA™ with implanted neuromuscular interfaces is revealed. The system has been used by the patient since January 2013. This breakthrough is the result of a collaboration between Integrum, Chalmers University of Technology and Sahlgrenska University Hospital. The official press release can […]

read more
28 Aug 2014

Lecture by Max Jair Ortiz Catalan

Max Jair Ortiz Catalan from Integrum will give a short lecture on future control of arm and leg prosthetics at the National Life Science Day. The event takes place at Skogshem & Wijk, Lidingö on the 30th of September and the lecture will be at 11:20. Read more about it here.

read more
18 Aug 2014

Study from Chalmers University of Technology

In February this year, a study from Chalmers University of Technology, that was supported by Integrum, that demonstrated a novel treatment for phantom limb pain (PLP) was published. The treatment successfully reduced the pain levels for a chronic PLP patient, for whom no other treatments had been successful. A multi-centre clinical trial verifying the results from this […]

read more
09 Jun 2014

Lecture by Dr. Todd Kuiken

Dr. Todd Kuiken from the Rehabilitation Institute of Chicago is giving a lecture on Developing Neural Interfaces for Robotic Prostheses at Chalmers Wednesday the 11th of June at 15:00-16:00.  The lecture is taking place at the EC-room, EDIT-building at Hörsalsvägen 11

read more
07 May 2014

Vetenskapsfestivalen

Researchers from Integrum will participate in Vetenskapsfestivalen (The Science Festival) in Gothenburg Friday the 9th of May to present research in naturally controlled prosthetics. Research engineers Morten Bak Kristoffersen and Alejandra Zepeda will have a presentation followed by a 2-hour demonstration at 13:00 in Nordstan and research engineer Max Ortiz Catalan will  give a lecture at 19:30 […]

read more
19 Mar 2014

Vinnova

Integrum just received 5 out of 65 million SEK for innovative small and medium sized companies from Vinnova. The funding is for further development in osseointegrated nerve and muscle controlled prosthetics with sensory feedback. The press release from Vinnova can be read here (in Swedish)

read more
16 Mar 2014

Presentation

Dr. Örjan Berlin will do a oral presentation titeled An osseointegrated percutaneous prosthetic system for the treatment of patients with transfemoral amputation: Results from the OPRA technique at EMSOS 2014 Friday the 23rd of Maj.

read more
28 Feb 2014

Björn Rydevik talks about osseointegrated amputation prostheses

On Friday March 7, at the Swedish Embassy in Tokyo, Professor Björn Rydevik will talk about osseointegrated amputation prostheses. Click here for more information.

read more
26 Feb 2014

A new study

A new study from Chalmers University of Technology and the Center of Orthopaedic Osseointegration on the treatment of phantom limb pain (PLP) has been published today. The study presents a novel treatment that has successfully reduced the pain levels for a chronic PLP patient for whom other treatments have not worked. The study has been […]

read more
30 Jan 2014

Prospective clinical study

The first prospective clinical study of 51 patients treated with an osseointegrated prosthetic system for transfemoral amputation is published in the Bone and Joint Journal. The study presents a cumulative survival rate of 92% at two years combined with enhanced prosthetic use and mobility, fewer problems and improved quality of life, which supports the ‘revolutionary […]

read more
13 Dec 2013

The main feature

Christoffer Lindhe, who is a trilateral amputee with two fixtures osseointegrated into the bones, is the main feature in the newest edition of Ingenjören (eng. The Engineer). The article is about his accident, life and his work to bring his own prosthetic foot to the market. The article is available here (pdf, page 25).

read more
25 Oct 2013

A new team

The new team at Centro Hospitalar do Porto in Portugal has performed their first surgery with the OPRA Implant System. We welcome Dr. Cantista, Dr. Cardoso, Dr. Oliviera and their team and look forward to our future collaboration.

read more